Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea · Delayed Price · Currency is KRW 10,300
+70 (0.68%)
At close: Apr 10, 2026
Daewon Pharmaceutical Revenue
In the year 2025, Daewon Pharmaceutical had annual revenue of 605.43B KRW with 1.22% growth. Daewon Pharmaceutical had revenue of 159.81B in the quarter ending December 31, 2025.
Revenue
605.43B
Revenue Growth
+1.22%
P/S Ratio
0.36
Revenue / Employee
471.89M
Employees
1,283
Market Cap
219.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 605.43B | 7.27B | 1.22% |
| Dec 31, 2024 | 598.16B | 71.21B | 13.51% |
| Dec 31, 2023 | 526.95B | 48.07B | 10.04% |
| Dec 31, 2022 | 478.88B | 124.71B | 35.21% |
| Dec 31, 2021 | 354.18B | 45.68B | 14.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 959.01B |
| Suheung | 722.31B |
| Jeil Pharmaceutical Co.,Ltd | 567.24B |
| Samjin Pharmaceuticals | 274.03B |
| Ilyang Pharmaceutical Co.,Ltd | 272.42B |
| JW Lifescience | 257.83B |
| Whan In Pharm | 255.21B |
| Samil Pharmaceutical Co.,Ltd | 210.25B |